1. Signaling Pathways
  2. GPCR/G Protein
  3. Prostaglandin Receptor

Prostaglandin Receptor

Prostaglandin receptor, a sub-family of cell surface seven-transmembrane receptors, are the G-protein-coupled receptors. There are currently ten known prostaglandin receptors on various cell types. Prostaglandins bind to a subfamily of cell surface seven-transmembrane receptors, G-protein-coupled receptors. These receptors are named: DP1-2-DP1, DP2 receptors, EP1-4-EP1, EP2, EP3, EP4 receptors, FP-FP, IP1-2-IP1, IP2 receptors, TP-TP receptor. The prostaglandins are a group of hormone-like lipid compounds that are derived enzymatically from fatty acids and have important functions in the animalbody. There are currently ten known prostaglandin receptors on various cell types.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-109163
    Treprostinil palmitil
    Agonist 99.62%
    Treprostinil palmitil is a long-acting inhaled pulmonary vasodilator prodrug of Treprostinil (HY-100441), formulated in a lipid nanoparticle (LNP). Treprostinil palmitil can inhibit pulmonary vascular remodeling induced by Su/Hx challenge in rats. Treprostinil palmitil can induce cough. Treprostinil palmitil demonstrates a sustained presence in the lungs with reduced systemic exposure and prolonged inhibition of hypoxia-induced pulmonary vasoconstriction in vivo. Treprostinil palmitil can be studied in research for pulmonary arterial hypertension and interstitial lung disease.
    Treprostinil palmitil
  • HY-N0223
    Epibetulinic acid
    Inhibitor ≥98.0%
    Epibetulinic acid exhibits potent inhibitory effects on NO and prostaglandin E2 (PGE2) production in mouse macrophages (RAW 264.7) stimulated with bacterial endotoxin with IC50s of 0.7 and 0.6 μM, respectively. Anti-inflammatory activity.
    Epibetulinic acid
  • HY-121018
    Daltroban
    Antagonist 98.1%
    Daltroban (BM-13505) is a selective and specific thromboxane A2 (TXA2) receptor antagonist. Daltroban increase intracellular calcium in vascular smooth muscle cells. Daltroban shows protective effect in reperfusion injury.
    Daltroban
  • HY-50848
    BW A868C
    Antagonist 99.00%
    BW A868C, a hydantoin compound, is a BW245C structural analogue. BW A868C is a selective and potent competitive prostaglandin D2 (PGD2) antagonist. BW A868C has no effect on other prostaglandin receptors (IP, EP1, EP2, TP and FP).
    BW A868C
  • HY-19361
    L-826266
    Antagonist ≥98.0%
    L-826266 is a selective and competitive EP3 receptor antagonist. L-826266 can be used for convulsive disorders research.
    L-826266
  • HY-114141
    BI-671800
    Antagonist 99.36%
    BI-671800 is a highly specific and potent antagonist of chemoattractant receptor-homologous molecule on Th2 cells (DP2/CRTH2), with IC50 values of 4.5 nM and 3.7 nM for PGD2 binding to CRTH2 in hCRTH2 and mCRTH2 transfected cells, respectively. BI-671800 has potential for the treatment of poorly controlled asthma.
    BI-671800
  • HY-122168
    AAT-008
    Antagonist 98.55%
    AAT-008 is a potent, selective, and orally active prostaglandin EP4 receptor antagonist with Kis of 0.97 and 6.1 nM for recombinant human EP4 and recombinant rat EP4, respectively.
    AAT-008
  • HY-135259
    CAY10580
    Agonist
    CAY10580 is a potent and selective prostaglandin EP4 receptor agonist (Ki=35 nM).
    CAY10580
  • HY-128039
    17-Phenyl-ω-trinor-PGE2
    Agonist ≥98.0%
    17-Phenyl-ω-trinor-PGE2 is a PGE2 (HY-101952) analog, which is an agonist for EP1 and EP3 receptor. 17-Phenyl-ω-trinor-PGE2 inhibits the PAF-induced aggregation of human platelet-rich plasma (PRP) and Cicaprost (HY-19583) induced Cyclic AMP (HY-B1511) production.
    17-Phenyl-ω-trinor-PGE2
  • HY-108560
    (+)-Fluprostenol
    Activator
    (+)-Fluprostenol is a potent agonist of PTGER2. (+)-Fluprostenol decreases the expression of Oviductal glycoprotein 1 (OVGP1).
    (+)-Fluprostenol
  • HY-B0428A
    Ozagrel sodium
    Inhibitor 99.98%
    Ozagrel sodium (OKY-046 sodium) is a high selective and orally active thromboxane A2 (TXA2) synthase inhibitor with an IC50 of 11 nM. Ozagrel sodium exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA2 and increasing the production of prostacyclin (PGI2). Ozagrel sodium can be used for the study of ischemic stroke, asthma and thromboembolic diseases.
    Ozagrel sodium
  • HY-106067A
    Dazoxiben hydrochloride
    Inhibitor 99.90%
    Dazoxiben hydrochloride is a potent and orally active thromboxane (TX) synthase inhibitor.
    Dazoxiben hydrochloride
  • HY-15853
    MK-7246
    Antagonist 99.63%
    MK-7246 is a potent and selective CRTH2 antagonist with a Ki of 2.5±0.5 nM.
    MK-7246
  • HY-102065
    SC-19220
    Antagonist 99.71%
    SC-19220 is a competitive prostaglandinn E2 receptor antagonist. SC-19220 increases the bladder capacity and reduced the voiding efficiency of micturition (elicited by slow transvesical filling) of urethane-anesthetized rats. SC-19220 can restores the balance in bone marrow granulocyte and monocyte production after burn sepsis.
    SC-19220
  • HY-130223
    11β-Prostaglandin E2
    Inhibitor ≥99.0%
    11β-Prostaglandin E2 (11β-Dinoprostone), a Prostanoid derivative, inhibits [3H]PGE2 binding to hypothalamic membranes in the rat with a Ki of 53.3 nM.
    11β-Prostaglandin E2
  • HY-139419
    Bimatoprost grenod
    Agonist 98.34%
    Bimatoprost grenod (NCX 470) is a second-generation nitric oxide (NO)-donating prostaglandin analogue. Bimatoprost grenod effectively lowers intraocular pressure (IOP) in animal models of ocular hypertension and glaucoma by activating bimatoprost-mediated uveoscleral outflow and NO mediated conventional outflow. Bimatoprost grenod can be used for the research of cular hypertension and glaucoma.
    Bimatoprost grenod
  • HY-114910
    11-Deoxy Prostaglandin E2
    Agonist ≥99.0%
    11-Deoxy Prostaglandin E2 is a selective agonist of EP4 with an EC50 of 0.66 nM. 11-Deoxy Prostaglandin E2 is an analog of prostaglandin E2. 11-Deoxy Prostaglandin E2 can be used in study bone healing, heart failure, and other receptor associated conditions.
    11-Deoxy Prostaglandin E2
  • HY-17357S
    Nepafenac-d5
    Inhibitor 98.84%
    Nepafenac-d5 (AHR-9434-d5; AL-6515-d5) is the deuterium labeled Nepafenac (HY-17357). Nepafenac, a nonsteroidal anti-inflammatory agent, is a topically administered COX-2 inhibitor with an IC50 of 0.12 μM. Nepafenac exhibits only weak COX-1 inhibitory activity (IC50 = 64.3 μM). Nepafenac possesses unique prodrug properties, which enable it to rapidly convert into the active metabolite Amfenac (HY-17479) in the ocular tissues, thereby achieving high concentrations in the retina and choroid. Nepafenac reduces inflammation and pain by inhibiting the activity of cyclooxygenase (COX) enzymes and thereby decreasing the production of prostaglandin PGE. Nepafenac can delay the metastasis of uveal melanoma (UM) in rabbit eyes. Nepafenac is mainly used for pain management and inflammation control after ophthalmic surgeries.
    Nepafenac-d<sub>5</sub>
  • HY-118941
    BAY 73-1449
    Antagonist 99.99%
    BAY 73-1449 is a selective antagonist of prostacyclin receptor (IP), with high potency (IC50 of less than 0.1 nM) in cAMP assays in Human HEL cells and rat DRG. BAY 73-1449 can be used in the research of lowering blood pressure.
    BAY 73-1449
  • HY-N0761A
    trans-Isoferulic acid
    Inhibitor 99.93%
    trans-Isoferulic acid (trans-3-Hydroxy-4-methoxycinnamic acid) is an aromatic acid isolated from the roots of Clematis florida var. plena. trans-Isoferulic acid exhibits anti-inflammatory activity.trans-isoferulic acid suppresses NO and PGE2 production through the induction of Nrf2-dependent heme oxygenase-1 (HO-1).
    trans-Isoferulic acid
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.